Macartney K K, Beutels P, McIntyre P, Burgess M A
National Centre for Immunisation Research and Surveillance of Vaccine Preventable Diseases (NCIRS), The Children's Hospital at Westmead, New South Wales, Australia.
J Paediatr Child Health. 2005 Nov;41(11):544-52. doi: 10.1111/j.1440-1754.2005.00717.x.
Varicella zoster virus (VZV) causes both chickenpox and herpes zoster and is responsible for a significant disease burden, including hospitalizations and deaths, in Australian children and adults. Varicella vaccine has been available in Australia for 5 years; however, from November 2005, it will be funded for use in all susceptible children at 18 months and 10-13 years of age under the National Immunisation Program. Experience with universal varicella vaccination of children in the USA over the last 10 years has shown that the vaccine is safe and highly effective in reducing varicella-related disease. This review summarizes the epidemiology of VZV-related disease in Australia, the use of varicella vaccine and the international experience with vaccine efficacy and safety. The potential impact of varicella vaccination on the incidence of herpes zoster is also discussed.
水痘带状疱疹病毒(VZV)可引起水痘和带状疱疹,在澳大利亚儿童和成人中造成了包括住院和死亡在内的重大疾病负担。水痘疫苗在澳大利亚已上市5年;然而,从2005年11月起,根据国家免疫规划,它将被资助用于所有18个月大以及10至13岁的易感儿童。过去10年美国对儿童进行普遍水痘疫苗接种的经验表明,该疫苗在减少水痘相关疾病方面安全且高效。本综述总结了澳大利亚VZV相关疾病的流行病学、水痘疫苗的使用情况以及疫苗效力和安全性方面的国际经验。还讨论了水痘疫苗接种对带状疱疹发病率的潜在影响。